about
The role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantationBone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adultsBone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for haematological malignanciesThe role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantationAllogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphomaPolyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adultsAllogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphomaPolyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell/bone marrow transplantationCritical care of patients with cancerExpert statements on the standard of care in critically ill adult patients with atypical haemolytic uraemic syndrome.[Sepsis: new findings and developments. Update 2016].Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma?Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.CD40-activated B cells induce anti-tumor immunity in vivo.CCC meets ICU: redefining the role of critical care of cancer patients.Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.Characterization of tumor-associated B-cell subsets in patients with colorectal cancer.DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantationPD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiotaImmortalized B cells: a neverending source of antigen-presenting cells for vaccines?T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals.CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.The role of B cells in the pathogenesis of graft-versus-host disease.Toll-like receptor 9 agonists as cancer therapeutics.The cyclins: a family of widely expressed tumor antigens?Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis.CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application.Overcoming tumor-mediated immunosuppression.Generation of human CD40-activated B cells.Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis.Murine model of CD40-activation of B cells.Should we be combining local tumor therapies with immunotherapies as standard?The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations.Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells.Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors.Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation.Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective.
P50
Q24186279-DE903266-8553-4D33-8BDA-86B79D677AFBQ24195048-11350FB0-76D8-4A04-8CFC-F2C8AEEBE367Q24197741-FCFA2A08-EA73-4B86-992A-0B2BF871C8DAQ24198004-21884871-8DC1-49BB-A209-1A7CC5053114Q24200183-9BEB8952-2A3B-46DD-8FAF-29002E87F17AQ24200813-5D33A7E7-C9FF-4749-BEED-E571B7036C36Q24203887-6B0BF35F-37AC-479A-90A3-E0D1F9D97F61Q24234072-411CE26A-9572-4B71-A8D7-6D99E3385D7BQ26746976-060A5A0D-E87B-410B-87B8-2713845E1998Q30234666-FBF11541-9AE7-4967-A3F6-BF937C666817Q30244870-14535E59-3416-4477-AF4F-DB89AB6D1E72Q33385493-20C91606-86E0-47FC-8709-5BAC713D28A1Q33405002-EF3130E2-402C-4F44-BCE0-5546C2A9EFD3Q33709425-4D1F8305-2825-4F68-B4F8-C6D9688E4AD7Q33741056-83341EBC-05E0-4344-A289-B7C65E4DBC8EQ33886261-A72C739A-226D-4438-9663-6BE1D0FFF7CEQ34103969-40B7EB97-E825-4608-BDE1-998473F10C05Q35941917-8ABBA334-2EF3-44BF-8E79-C358DC9EEF16Q36833808-1F736A77-FC73-4E7E-8445-4F19C0465F69Q37012531-C9828639-BD41-457B-A6DC-1D1DE28B6CE7Q37079102-B75EA637-3F71-4942-9E41-22AE8672C7B0Q37150312-70ABA6B0-CE3A-4F32-B257-ACF7DB0949FEQ37256021-BBF9ADBE-FED0-41F8-AD07-1D5BDB49A65CQ37327528-C97A35D9-4B95-4BCB-A41A-57BE3D86957CQ37596195-7AABBC40-BDE2-42FC-8270-496F1FE19140Q37831323-5A44D2DB-AE80-4C87-BD90-0ECB30516861Q37857261-6ABA74E5-187A-4ABF-BFBA-FD970AD0929EQ38096525-12C39953-0684-406A-9883-F45393C875B8Q38113268-ADC1DBB3-85DC-4393-9B90-963A07491C96Q38262255-24DE348D-69B6-47BE-825F-975CEE0A5F8CQ38272355-F7864B52-FA1A-4BA8-85FD-6572B3024861Q38325654-8BBDDC5E-1249-42B0-B42C-91698C62BA11Q38332142-8DFBC2F9-74F6-4827-8234-23DEF9FB4537Q38638858-F18D3A21-3D2E-4FC1-AA84-69C93A3B2542Q38722598-88AC1F7A-BC25-49CB-BB30-4C68550A1920Q38986039-298A5B42-4B59-4236-A626-D072959AFF47Q39117820-630DD7F1-E724-43E6-A79B-ED7C7A6D4A26Q39208496-6E6EEBC5-EB97-42A3-B48E-A9434197C263Q39250776-7D098DDF-B7A8-43F8-BBA4-0151041EC8E0Q39302484-9137AC4B-6D86-45D0-9691-5C99B9DB70D3
P50
name
Michael von Bergwelt-Baildon
@ast
Michael von Bergwelt-Baildon
@en
Michael von Bergwelt-Baildon
@es
Michael von Bergwelt-Baildon
@fr
Michael von Bergwelt-Baildon
@nl
type
label
Michael von Bergwelt-Baildon
@ast
Michael von Bergwelt-Baildon
@en
Michael von Bergwelt-Baildon
@es
Michael von Bergwelt-Baildon
@fr
Michael von Bergwelt-Baildon
@nl
altLabel
Michael S von Bergwelt-Baildon
@en
Michael S. von Bergwelt-Baildon
@en
prefLabel
Michael von Bergwelt-Baildon
@ast
Michael von Bergwelt-Baildon
@en
Michael von Bergwelt-Baildon
@es
Michael von Bergwelt-Baildon
@fr
Michael von Bergwelt-Baildon
@nl